162237-91-4

Upstream product

• 100-39-0 benzyl bromide 
• 510730-56-0 (R)-3-(benzyloxy)-2-phenylpropanoic acid 
• 60656-87-3 benzyloxyacetoaldehyde 
• 56613-80-0 D-2-phenylglycinol 
• 393536-17-9 (R)-N-[(1E)-2-(benzyloxy)ethylidene]-2-methylpropane-2-sulfinamide 
• 510730-52-6 (4S,2'R)-3-((2'-benzyloxymethyl)phenylacetyl)-4-(phenylmethyl)-2-oxazolidinone 
• 3587-60-8 Benzyloxymethyl chloride 
• 860304-23-0 (R)-2-N,N-diallylamino-2-phenylethanol 
• 860304-25-2 N,N-diallyl-N-[(1R)-2-(benzyloxy)-1-phenylethyl]amine 
• 510730-61-7 (R)-3-Benzyloxy-2-phenyl-propionamide 
• 342651-78-9 (R_S,1R)-2-methylpropane-2-sulfinic acid (2-benzyloxy-1-phenylethyl)amide 
• 100-44-7 benzyl chloride 

Downstream Products

• 185250-30-0 ((R)-2-Benzyloxy-1-phenyl-ethyl)-(2-bromo-allyl)-amine 
• 680594-91-6 ((R)-2-Benzyloxy-1-phenyl-ethyl)-[1-phenyl-meth-(E)-ylidene]-amine 
• 510730-65-1 (2-benzyloxy-1-phenyl-ethyl)-carbamic acid tert-butyl ester 
• 860304-27-4 tert-butyl (3aR,4R,6aS)-4-({[(1R)-2-(benzyloxy)-1-phenylethyl]amino}methyl)-2,2-dimethyltetrahydro-5H-[1,3]dioxolo[4,5-c]pyrrole-5-carboxylate 
• 33125-05-2 Boc-D-Phg-OH 
• 25705-52-6 (R)-phenylglycine hydrochloride 
• 67341-01-9 (R)-N-(tert-butoxycarbonyl)phenylglycinol 
• 1451214-41-7 C₁₆H₂₅NO₂ 
• 1451214-40-6 (1’R,3S,6S)-1-(2’-hydroxy-1’-phenylethyl)-6-propylpiperidin-3-ol 
• 1451214-34-8 C₂₂H₂₇NO₃ 
• 1451214-42-8 C₁₅H₁₉NO₃ 
• 1451214-35-9 (1’R,2S)-2-(2’-benzyloxy-1’-phenylethylamino)-4-[1,3]dioxolan-2-ylbutyl acetate 
• 1451214-36-0 (1’R,2S)-[1-(2’-benzyloxy-1’-phenylethyl)pyrrolidin-2-yl]methanol 
• 1451214-37-1 (1S,1’R)-1-[(2’-benzyloxy-1’-phenylethylamino)methyl]-3-[1,3]dioxolan-2-ylpropyl acetate 

Relevant academic research and scientific papers

PYRIMIDINEDIONE COMPOUNDS AGAINST CARDIAC CONDITIONS

Provided are novel pyrimidine dione compounds and pharmaceutically acceptable salts thereof, that are useful for the treatment of hypertrophic cardiomyopathy (HCM) and conditions associated with left ventricular hypertrophy or diastolic dysfunction. The synthesis and characterization of the compounds and pharmaceutically acceptable salts thereof, are described, as well as methods for treating HCM and other forms of heart disease.

Origins of stereoselectivity in optically pure phenylethaniminopyridine tris-chelates M(NN′)3n+ (M = Mn, Fe, Co, Ni and Zn)

One-pot reactions of 2-pyridinecarboxaldehyde, chiral phenylethanamines and Fe(ii) give single diastereomer fac diimine complexes at thermodynamic equilibrium so that no chiral separations are required (d.r. > 200:1). The origins of this stereoselectivity are partly steric and partly a result of the presence of three sets of inter-ligand parallel-offset π-stacking interactions. Mn(ii), Co(ii), Co(iii), Ni(ii) and Zn(ii) give similar fac structures, alongside the imidazole analogues for Fe(ii). While most of the complexes are paramagnetic, the series of molecular structures allows us to assess the influence of the π-stacking present, and there is a strong correlation between this and the M-N bond length. Fe(ii) is close to optimal. For the larger Zn(ii) ion, very weak π-stacking leads to poorer measured stereoselectivity (NMR) but this is improved with increased solvent polarity. The mechanism of stereoselection is further investigated via DFT calculations, chiroptical spectroscopy and the use of synthetic probes.

Functionalized pyrrolidines inhibit α-mannosidase activity and growth of human glioblastoma and melanoma cells

New substituted pyrrolidine-3,4-diol derivatives were prepared from D-(-)- and L-(+)-phenyl glycinol. The influence of the configuration and the substitution of the lateral side chain of these derivatives on the inhibition of 25 commercial glycosidases we

Synthesis of chiral α-amino acids

A novel method for the synthesis of chiral α-amino acids has been developed where the acid functionality was constructed by oxidizing a hydroxymethyl group introduced by Evans' method in the α-position of an appropriate acid substrate and the amino part came from the amide of the original carboxyl group following a modified Hofmann rearrangement reaction.

Asymmetric synthesis of protected 1,2-amino alcohols using tert-butanesulfinyl aldimines and ketimines

tert-Butanesulfinyl aldimines and ketimines bearing an α-benzyloxy or α-silyloxy substituent serve as precursors in the synthesis of protected 1,2-amino alcohols in high yields and diastereoselectivities. General protocols are described for the addition of unbranched alkyl, branched alkyl, and aryl organometallic reagents to N-sulfinyl aldimines 1 and 2 and ketimines 5 and 6. Furthermore, the selective N- or O-deprotection of sulfinamide products 3, 4, 7, and 8 is described, enabling further synthetic transformations of the reaction products.

A facile three-step synthesis of 1,2-amino alcohols using the Ellman homochiral tert-butylsulfinamide

Addition of organometallic reagents to tert-butylsulfinimines derived from tert-butyldimethylsiloxyacetaldehyde stereoselectively generates protected 1,2-amino alcohols. Removal of the acid labile protecting groups affords amino alcohols in high yield. The predominant diastereomer is opposite to that predicted by the traditional Ellman model; therefore, a chelation model invoking rapid E/Z isomerization of the imine is proposed to rationalize the observed selectivity.

Synthesis of chiral, nonracemic methyleneaziridines derived from β-amino alcohols

An efficient three step process for the synthesis of chiral, nonracemic methyleneaziridines derived from homochiral β-amino alcohols is described. Methyleneaziridines 4a-e produced using this chemistry have been shown to possess high enantiomeric purities